CAR T-cell therapy for leukemia leads to remissions in clinical trial

Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy. The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph node scan. …read more

Source: EurekAlert

(Visited 6 times, 1 visits today)

Popular Posts